Cargando…
Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury
A screen by Kost-Alimova et al.(1) suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670931/ https://www.ncbi.nlm.nih.gov/pubmed/33225317 http://dx.doi.org/10.1016/j.xcrm.2020.100145 |